RESEARCH ARTICLE

Virological and immunological failure of HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia

Genet Gebrehiwet Hailu1,2, Dawit Gebregziabher Hagos1, Amlsha Kahsay Hagos1, Araya Gebreyesus Wasihun1,*, Tsehay Asmelash Dejene1,3

1 College of Health Sciences, Department of Medical Microbiology and Immunology, Mekelle University, Mekelle, Tigray, Ethiopia, 2 College of Health Sciences, Ayder Comprehensive Specialized Hospital, Department of Laboratory Mekelle University, Mekelle, Tigray, Ethiopia, 3 College of Health Sciences, Department of Medical Microbiology, Axum University, Tigray, Ethiopia

* araya13e2@gmail.com, araya.gebreyesus@mu.edu.et

Abstract

Background

Human immunodeficiency virus/Acquired immunodeficiency syndrome associated morbidity and mortality has reduced significantly since the introduction of highly active antiretroviral therapy. As a result of increasing access to highly active antiretroviral therapy, the survival and quality of life of the patients has significantly improved globally. Despite this promising result, regular monitoring of people on antiretroviral therapy is recommended to ensure whether there is an effective treatment response or not. This study was designed to assess virological and immunological failure of highly active antiretroviral therapy users among adults and adolescents in the Tigray region of Northern Ethiopia, where scanty data are available.

Methods

A retrospective follow up study was conducted from September 1 to December 30, 2016 to assess the magnitude and factors associated with virological and immunological failure among 260 adults and adolescents highly active antiretroviral therapy users who started first line ART between January 1, 2008 to March 1, 2016. A standardized questionnaire was used to collect socio-demographic and clinical data. SPSS Version21 statistical software was used for analysis. Bivariate and multivariate logistic regression analyses were conducted to identify factors associated to virological and immunological failure. Statistical association was declared significant if p-value was \( \leq 0.05 \).

Result

A total of 30 (11.5%) and 17 (6.5%) participants experienced virological and immunological failure respectively in a median time of 36 months of highly active antiretroviral therapy.
Virological failure was associated with non-adherence to medications, aged < 40 years old, having CD4⁺ T-cells count < 250 cells/μL and male gender. Similarly, immunological failure was associated with non-adherence, tuberculosis co-infection and Human immunodeficiency virus RNA ≥1000 copies/mL.

Conclusions

The current result shows that immunological and virological failure is a problem in a setting where highly active antiretroviral therapy has been largely scale up. The problem is more in patients with poor adherence. This will in turn affect the global targets of 90% viral suppression by 2020. This may indicate the need for more investment and commitment to improving patient adherence in the study area.

Introduction

Though, there is no curative therapy for Human immunodeficiency virus (HIV), the introduction of highly active antiretroviral therapy (HAART) in the late 1990s has substantially decreased HIV associated morbidity and mortality, and increased patient survival [1–3]. Proper use of these medications have transformed the disease from an inevitably fatal disease to a chronic, treatable condition by suppressing the viral load to undetectable levels and providing a consistent increase in the number of CD4⁺ T lymphocytes [4,5].

Major challenges especially in low and middle income countries such as poor adherence to medications [6], defects in host immunity, development of drug resistance [7,8], toxicity, poor infrastructure and lack of specialized care and human resources [9] are factors hindering the success of HAART. Furthermore, there were more debates on the introduction of HAART particularly to sub-Saharan Africa mainly due to adherence concerns and subsequent development of drug resistance [10]. Even with these limitations, HAART has been significantly scaled up at global level as per the World Health Organization (WHO) recommendations [11].

HIV infected individuals on HAART are usually recommended to monitor clinically, immunologically and virologically on a regular manner to ensure successful treatment, identify adherence problems and determine whether HAART regimens should be switched or not. Compared to clinical or immunological monitoring, virological monitoring provides an early and more accurate indication of treatment failure and the need to switch from first-line to second-line drugs, reduce the accumulation of drug resistance mutations and improving clinical outcomes. However, due to the high costs and technical demands of the test, clinical and immunological assessments are usually recommended to start and monitor the efficacy of therapy [12]. As a result, patients may be at risk of unrecognized virologic failure, subsequent development of drug resistance and to continue with failed regimen.

As of 2016, 19.5 million people living with HIV were accessing ART with an approximate coverage of 53%. Of these, 11.7 million people accessing ART were from East and southern Africa with coverage of 60% [13]. Ethiopia is one of the sub-Saharan African countries with high burden of HIV infection, estimated adult prevalence 1.1% (0.8% in males and 1.5% in females) and 0.03% incidence. In Ethiopia HAART began in 2003 and scale up in 2005. Since then, a total of 375,811 people living with HIV (PLWH) were actively on HAART by 2015 with 82.8% ART coverage [14], and improved health and survival of patients in many parts of Ethiopia [15].
There are substantial numbers of ART users in the Tigray regional state [16], however, there is no data on the immunological and virological outcomes of HAART. Hence, addressing this knowledge gap is reasonable to help public health planners, policy makers and implementers to plan and design appropriate intervention strategies in order to prevent the disease.

**Materials and methods**

**Study area and sample size determination**

The study was conducted in Mekelle Hospital (MH) and Ayder Comprehensive Specialized Hospital (ACSH), both located in Mekelle city. Mekelle, the capital city of Tigray Regional state is located 783 Km north of Addis Ababa, the capital city of Ethiopia. There are five public hospitals in the city. These two hospitals were selected purposely due to their higher flow of patients. MH is administered by the Tigray Regional Health Bureau, whereas ACSH is a University hospital under the Federal Ministry of Education. According to the information obtained from the ART clinics, by May 2016 there were about 8,727 and 1,564 people living with HIV (PLHIV) ever enrolled; 6,789 and 1,387 ever started ART; 4,189 and 1,222 were actively on ART in MH and ACSH, respectively. The sample size (n = 260) was determined using the single mean proportion formula.

**Study design and data collection procedures.** A retrospective follow up study was used on HIV infected individuals on first line ART. Base line and follow up clinical and laboratory data were collected from each study participants’ medical records using checklists. In addition, socio demographic characteristics, clinical and laboratory data (viral load and CD4\(^+\) count) were also collected from each study participants prospectively using questionnaire during data collection period, September 1 to December 30, 2016.

**Study population and study variables.** The study population were adolescents (aged 10–19) and adults (≥20 years) who initiated HAART between January 1, 2008 and March 1, 2016. Patients who were less than 6 months on ART, who had been on second line regimen, lost to follow up, febrile, and transfer in were excluded from the study. Virological and immunological failures defined based on WHO consolidated guide line 2016 were the primary outcome variables of the study. Socio-demographic characteristics (age, gender, educational level, occupation, marital status and socio economic status) and information related to HIV infection and ART (date of ART initiation, route of transmission, time on ART, HIV prophylaxis given, presence/absence of opportunistic infections, nutritional status, types of drugs and regimen given, HBV and HCV co-infections, level of adherence, WHO clinical stage, and known chronic non communicable diseases) were the predictor variables.

**Laboratory testing methods.** RNA extraction and Plasma Viral load Determination: During the collection time we collected blood samples for each patient and did a single viral load using the standard procedure. Briefly, HIV-1 RNA was extracted from 0.2 mL of plasma using Abbott m2000sp automated sample preparation system (Abbott Molecular, USA) in Tigray Health Research Institution (THRI). Extracted RNAs were measured using Abbott m2000rt quantitative Real Time HIV-1 assay (Abbott Molecular, USA) with HIV-1 RNA detection level of 40 to 10 million copies/mL based on the manufacturer’s procedures.

CD4\(^+\) count: Data on CD4\(^+\) T-cells count which was measured at baseline and every six months of interval then after during regular follow up visit was collected from medical charts. In addition, we have also collected blood samples from each participant during the data collection period and measured CD4+ count at ACSH ART laboratory using the BD FACSCount™ (Becton Dickinson, USA) following the manufacturer’s protocol (“Fig 1”).

**Data quality assurance, processing and analysis.** Quality of laboratory data was kept by strictly following standard operational procedures during sample collection, handling and
Arrivals of participants at regular follow up during study period (September - December, 2016)

260 patients fulfilled inclusion criteria

Collection of blood for CD4 count and viral load measurement and Sent to: ACSH for CD4 count and THRI for VL test

Collection of data retrospectively and prospectively

Immunological outcome

Virological outcome

Fall at or below 250 cells/μL following clinical failure or persistent CD4 count below 100 cells/μL

Yes

Immunological failure

No

Immunological success

Viral load < 1000 copies/ml

Viral load ≥ 1000 copies/ml

Virological Success

Virological failure

Fig 1. Work flow of the study.

https://doi.org/10.1371/journal.pone.0196259.g001

transportation. Negative, low positive and high-positive (during viral load determination); and low, medium and high controls (during CD4⁺ count) were included in each test to evaluate run validity. Furthermore, CD4⁺ and viral load reagents were checked for expiry date. Filled forms and questionnaires were checked for completeness and consistency daily during data collection period by principal investigator.

Data was entered and validated using Epidata version 3.1 and exported to SPSS version 22 for statistical analyses. Descriptive statistics, such as median and inter quartile ranges (IQR) was used to compute continuous variables and counts with percentage for categorical variables. Binary and multiple logistic regressions were used to examine the relationships of independent variables with the primary outcomes. A p-value of \( \leq 0.05 \) with 95% confidence interval was considered as statistically significant correspondingly.
Ethical considerations. Institutional ethical clearance was obtained from the Mekelle University, College of Health Sciences Ethical Review Committee (ERC0816/2016). Written informed consent or assent was also obtained from study participants and/or families and/or guardians. Furthermore, permissions were also obtained from Tigray regional health bureau and medical directors of Mekelle hospital and Ayder Compressive Specialized hospital. Each data was kept confidentially using codes and initials instead of names. CD4⁺ and viral load results were attached with the patients’ medical records to be used as follow up and base line data respectively. Study participants who had virological and immunological failures were linked with responsible health professionals for proper management.

Results

Socio demographic data of study participants

A total of 260 HIV infected individuals on first line ART regimen were included in the study, of which 151 (58.1%) of them were females. The minimum and maximum age of the participants was 10 and 63 years old, respectively with median age of 39 (IQR: 32–48) years old. One hundred seventeen (45.0%) were married, and 229 (88.1%) of the study participants were infected through sexual contact. The majority 197 (75.8%) of the study participants were attended primary school and above. One hundred four (40%) of them were self-employed with a median income of 1500 birr. Urban dwellers accounted 211 (81.2%) of the participants (Table 1).

Immunological failure and associated risk factors

Study participants were on first line HAART for 6 to 108 months with a median follow up time of 36 months. The baseline median CD4⁺ count was 162 cells/uL (IQR: 85–269) and

Table 1. Socio demographic characteristics of HIV infected individuals on ART from January 1, 2008 to March 1, 2016 at Mekelle hospital and Ayder Comprehensive Specialized Hospital (n = 260).

| Characteristics                                      | Frequency (%) |
|------------------------------------------------------|---------------|
| Gender                                               |               |
| Male                                                 | 109 (41.9)    |
| Female                                               | 151 (58.1)    |
| Age group at initiation of ART (years)               |               |
| 10–19                                                | 23 (8.8)      |
| 20–29                                                | 54 (20.8)     |
| 30–39                                                | 96 (36.9)     |
| 40–49                                                | 63 (24.2)     |
| 50–60                                                | 24 (9.2)      |
| Age group in median time of 36 months on ART (years)|               |
| 10–19                                                | 21 (8.0)      |
| 20–29                                                | 28 (10.8)     |
| 30–39                                                | 92 (35.4)     |
| 40–49                                                | 59 (22.7)     |
| 50–63                                                | 60 (23.1)     |
| Residence                                            |               |
| Rural                                                | 49 (18.8)     |
| Urban                                                | 211 (81.2)    |
| Educational level                                    |               |

(Continued)
Increased by 116 cells/μL, and reached 278 (IQR: 172–413) cells/μL after 6 months of HAART. It further increased to 300, 336, 395 and 398 cells/μL after 12, 18, 24 and 30 months of HAART, respectively ("Fig 2").

In median time of 36 (IQR: 24–54) months of ART follow up, 17 (6.5%) of the study participants had persistent CD4+ count below 100 cells/μL, which is an indication of immunological failure. Among those who had history of opportunistic infections, 43 (16.5%) of them had oral/esophageal candidiasis (data not shown), 43 (16.5%) TB co-infection and 26 (10.0%) had chronic/acute diarrhea (data not shown). Self-report of participants showed that 242 (93.1%) of them were adherent to the treatment. 180 (69.2%) of the study participants were given Tenofovir (TDF) based ART regimen followed by Zidovudine (AZT) (21.2%) (Table 2).

Study participants were followed for a minimum of 6 and a maximum of 108 months with a median time of 36 (IQR: 24–54) months on ART. At baseline 136 (52.3%) of study participants were on clinical stage III/IV. Of the total, 186 (71.5%) of them had at least one or more history of opportunistic infections either at ART initiation or follow up period. Among those who had history of opportunistic infections, 43 (16.5%) of them had oral/esophageal candidiasis (data not shown), 43 (16.5%) TB co-infection and 26 (10.0%) had chronic/acute diarrhea (data not shown). Self-report of participants showed that 242 (93.1%) of them were adherent to the treatment. 180 (69.2%) of the study participants were given Tenofovir (TDF) based ART regimen followed by Zidovudine (AZT) (21.2%) (Table 2).

increased by 116 cells/μL, and reached 278 (IQR: 172–413) cells/μL after 6 months of HAART. It further increased to 300, 336, 395 and 398 cells/μL after 12, 18, 24 and 30 months of HAART, respectively ("Fig 2").

In median time of 36 (IQR: 24–54) months of ART follow up, 17 (6.5%) of the study participants had persistent CD4+ count below 100 cells/μL, which is an indication of immunological failure. The median age among those who had poor immunological recovery was 39 (IQR: 33–43) years. 9/17 (52.9%) and 10/17 (58.8%) of them were males and were given TDF 3TC EFV at base line respectively. In addition, 11/17 (64.7%), 11/17 (64.7%) and 7/17(41.2%) of them have history of malnutrition, opportunistic infections and non-adherence at least once respectively. Furthermore, 11/17 (64.7%) and 14/17 (82.4%) of them had CD4+ count < 100 cells/μL and WHO clinical stage III/IV at base line respectively.

Non-adherent study participants were 5.68 times more likely to experience immunological failure (AOR (95% CI) = 5.68 (1.86–19.8), p = 0.021) compared with those who were good adherent by adjusting TB co-infections and viral load. Furthermore, it was statistically significant that patients having HIV RNA level ≥ 1000 copies/mL had 12.33 times higher odds of immunological failure (AOR (95% CI) = 12.33(3.06–29.7), p<0.0001) than those who had < 1000 copies/mL by adjusting other factors. Likewise, immunological failure was 3.8 times more likely to occur in TB.

Table 1. (Continued)

| Characteristics       | Frequency (%) |
|-----------------------|---------------|
| No formal education   | 63 (24.2)     |
| Primary               | 79 (30.4)     |
| Secondary             | 84 (32.3)     |
| Tertiary              | 34 (13.1)     |
| **Occupational status** |               |
| Gov't/ed             | 40 (15.3)     |
| Self employed         | 104 (40.0)    |
| Private employed      | 22 (8.5)      |
| Farmer                | 15 (5.8)      |
| Unemployed            | 57 (21.9)     |
| NA*                   | 22 (8.5)      |
| **Marital status**    |               |
| Widowed               | 19 (7.3)      |
| Single                | 62 (23.8)     |
| Married               | 117 (45.0)    |
| Divorced              | 41 (15.8)     |
| NA**                  | 21 (8.1)      |

Key

* NA- Not applicable for students
** NA- Not applicable for children <18 years old

Study participants were followed for a minimum of 6 and a maximum of 108 months with a median time of 36 (IQR: 24–54) months on ART. At baseline 136 (52.3%) of study participants were on clinical stage III/IV. Of the total, 186 (71.5%) of them had at least one or more history of opportunistic infections either at ART initiation or follow up period. Among those who had history of opportunistic infections, 43 (16.5%) of them had oral/esophageal candidiasis (data not shown), 43 (16.5%) TB co-infection and 26 (10.0%) had chronic/acute diarrhea (data not shown). Self-report of participants showed that 242 (93.1%) of them were adherent to the treatment. 180 (69.2%) of the study participants were given Tenofovir (TDF) based ART regimen followed by Zidovudine (AZT) (21.2%) (Table 2).

https://doi.org/10.1371/journal.pone.0196259.t001
Table 2. Baseline and follow up characteristics on first line ART from January 1, 2008 to March 1, 2016 at Mekelle hospital and Ayder Comprehensive Specialized Hospital (n = 260).

| Characteristics                        | N* (%)
|----------------------------------------|--------
| Time on ART (months)                   |        |
| 6–12                                   | 19 (7.3) |
| 13–24                                  | 56 (21.5) |
| 25–36                                  | 71 (27.3) |
| 37–48                                  | 45 (17.4) |
| >48                                    | 69 (26.5) |
| Route of transmission                  |        |
| Mother to child                        | 21 (8.1) |
| Heterosexual                           | 229 (88.1) |
| Blood transfusion                      | 10 (3.8) |
| Regimen given at base line             |        |
| TDF 3TCEFV/NVP*                         | 180 (69.2) |
| AZT 3TC NVP /EFV***                    | 55 (21.2) |
| D4T 3TC NVP /EFV*                      | 21 (8.1) |
| ABC 3TC EFV***                         | 4 (1.5) |
| WHO staging at base line               |        |
| I/II                                   | 124 (47.7) |
| III                                    | 107 (41.2) |
| IV                                     | 29 (11.2) |
| Adherence                              |        |
| Poor/Fair                              | 18 (6.9) |
| Good                                   | 242 (93.1) |
| Reason for non-adherence (n = 18)      |        |
| Side effects                           | 4 (22.2) |
| Forgot/Social problem                  | 10 (55.6) |
| Too ill                                | 4 (22.2) |
| History of malnourished                |        |
| Yes                                    | 83 (31.9) |
| No                                     | 177 (68.1) |
| Chronic NCDs***                        |        |
| Yes                                    | 12 (4.6) |
| No                                     | 248 (95.4) |
| History of OIs                         |        |
| Yes                                    | 186 (71.5) |
| No                                     | 74 (28.5) |
| TB Co-infection                        |        |
| Yes                                    | 43 (16.5) |
| No                                     | 217 (83.5) |
| HIV prophylaxis given                  |        |
| Yes                                    | 12 (4.6) |
| No                                     | 248 (95.4) |
| HBV Co-infection(n = 139)              |        |
| Yes                                    | 11 (7.9) |
| No                                     | 128 (92.1) |
| HCV Co-infection (n = 64)              |        |
| Yes                                    | 2 (3.1) |

(Continued)
co-infected individuals (AOR (95% CI) = 3.80 (2.01–12.90), p = 0.003) compared to TB non-infected individuals by adjusting adherence and high viral load (Table 3).

**Virological failure and associated risk factors**

Of the 260 participants, 221 (85%) of them had suppressed viral load (Plasma HIV RNA level: <150 copies/mL), 9 (3.5%) had 150–999 and 30 (11.5%) of them had high viral load (HIV RNA level ≥1000 copies/mL) after median time of 36 (IQR: 24–54) months on ART. Median viral load and CD4+ count among those who had an indication of virological failure (n = 30) was 12,239 (IQR: 2,548–43,622) copies/mL and 202 (IQR: 87–350) cells/μL respectively.

Virological failure was 16.37 times more likely to happen in non-adherent individuals (AOR (95% CI) = 16.37 (4.65–57.68), p < 0.001) compared with those who had good treatment adherence by adjusting gender, age and CD4+ count. Study participants aged less than 40 years old had 4.43 times more likely to experience virological failure than those who were older than...
Table 3. Immunological failure and associated risk factors among HIV infected individuals on ART from January 2008 to March 2016 at Mekelle hospital and Ayder Comprehensive Specialized Hospital (n = 17).

| Characteristics                          | Immunological failure | Binary logistic regression | Multiple logistic regression |
|------------------------------------------|-----------------------|---------------------------|----------------------------|
|                                          | Yes N (%)             | N* N (%)                  | p-value | OR(95%CI) | p-value | AOR(95%CI) |
| Gender                                   |                       |                           |         |           |         |            |
| Male                                     | 9(8.3)                | 100 (91.7)                | 0.35    | 0.62(0.23–1.67) |         |            |
| Female                                   | 8(5.3)                | 143(94.7)                 | 0.35    | 0.62(0.23–1.67) |         |            |
| Age group(years)                         |                       |                           |         |           |         |            |
| <40                                      | 10(7.1)               | 131(92.9)                 | 0.35    | 0.62(0.23–1.67) |         |            |
| ≥40                                      | 7(5.9)                | 112(94.1)                 | 0.69    | 0.82(0.30–2.22) |         |            |
| Age group at initiation of ART(years)    |                       |                           |         |           |         |            |
| <35                                      | 6(5.0)                | 115(95.0)                 | 0.34    | 1.65(0.59–4.60) |         |            |
| ≥35                                      | 11(7.9)               | 128(92.2)                 | 0.69    | 0.82(0.30–2.22) |         |            |
| CD4 + count at baseline(cells/μL)        |                       |                           |         |           |         |            |
| <250                                     | 16(10.1)              | 142(89.9)                 | NA      | NA        | NA      | NA         |
| >250                                     | 1(0.1)                | 101(99.9)                 | NA      | NA        | NA      | NA         |
| Time on ART(months)                      |                       |                           |         |           |         |            |
| <36                                      | 12(11.4)              | 93(88.6)                  | 0.014   | 0.26(0.088–0.78) | 0.068  | 0.32(0.093–1.87) |
| ≥36                                      | 5(3.2)                | 150(96.8)                 | 0.014   | 0.26(0.088–0.78) | 0.068  | 0.32(0.093–1.87) |
| Regimen given at base line               |                       |                           |         |           |         |            |
| TDF 3TC EFV                              | 10(6.1)               | 155(93.9)                 | NA      | NA        | NA      | NA         |
| AZT 3TCNVP                               | 1(2.8)                | 35(97.2)                  | NA      | NA        | NA      | NA         |
| AZT 3TC EFV                              | 3(15.8)               | 16(84.2)                  | NA      | NA        | NA      | NA         |
| Other                                    | 3(7.5)                | 37(92.5)                  | NA      | NA        | NA      | NA         |
| Adherence                                |                      |                           |         |           |         |            |
| Fair/poor                                | 7(38.9)               | 11(61.1)                  | 0.00    | 14.76(4.72–26.14) | 0.021  | 5.68(1.86–19.8) |
| Good                                     | 10(4.1)               | 232(95.9)                 | 0.00    | 14.76(4.72–26.14) | 0.021  | 5.68(1.86–19.8) |
| Viral load(copies/mL) in a median time of 36 months of ART |                       |                           |         |           |         |            |
| <1000                                    | 7(3.0)                | 223(97)                   | 0.00    | 15.93(5.47–26.38) | 0.00   | 12.33(3.06–29.7) |
| ≥1000                                    | 10(33.3)              | 20(66.7)                  | 0.00    | 15.93(5.47–26.38) | 0.00   | 12.33(3.06–29.7) |
| WHO clinical stage at base line          |                       |                           |         |           |         |            |
| I/II                                     | 3(2.4)                | 121(97.6)                 | NA      | NA        | NA      | NA         |
| III/IV                                   | 14(10.3)              | 122(89.7)                 | NA      | NA        | NA      | NA         |
| History of malnutrition                  |                       |                           |         |           |         |            |
| Yes                                      | 11(13.3)              | 72(86.7)                  | 0.005   | 0.23(0.082–0.65) | 0.24   | 0.47(0.14–1.65) |
| No                                       | 6(3.4)                | 171(96.6)                 | 0.005   | 0.23(0.082–0.65) | 0.24   | 0.47(0.14–1.65) |
| History of opportunistic infections      |                       |                           |         |           |         |            |
| Yes                                      | 11(7.7)               | 132(92.3)                 | 0.408   | 0.65(0.23–1.81) |         |            |
| No                                       | 6(5.1)                | 111(94.9)                 | 0.408   | 0.65(0.23–1.81) |         |            |
| Chronic non communicable diseases        |                       |                           |         |           |         |            |
| Yes                                      | 2(15.4)               | 11(84.6)                  | NA      | NA        | NA      | NA         |
| No                                       | 15(6.5)               | 232(93.5)                 | NA      | NA        | NA      | NA         |
| TB co-infection                          |                       |                           |         |           |         |            |
| Yes                                      | 7(16.3)               | 36(83.7)                  | 0.008   | 4.03 (1.44–11.26) | 0.003  | 3.80 (2.01–12.90) |
| No                                       | 10(8.5)               | 207(91.5)                 | 0.008   | 4.03 (1.44–11.26) | 0.003  | 3.80 (2.01–12.90) |
| Income(birr)                             |                       |                           |         |           |         |            |
| ≤1500                                    | 7(5.1)                | 129(94.9)                 | 0.35    | 1.62(0.60–4.38) |         |            |
| >1500                                    | 10(8.1)               | 114(91.9)                 | 0.35    | 1.62(0.60–4.38) |         |            |

HBV co-infection(n = 139)

(Continued)
40 years old (AOR (95%CI) = 4.43 (1.57–12.46), p = 0.005) by adjusting gender, adherence and CD4+ count. Likewise, being male was 4.6 times more likely to experience virological failure (AOD (95% CI) = 4.60 (1.72–12.33), p = 0.002) as compared to females by adjusting other factors. Furthermore, individuals having CD4+ count <250 cells/μL were 2.81 times more likely to develop virological failure (AOD (95% CI) = 2.81 (1.051–7.51), p = 0.04) as compare with those who have greater CD4+ count in a median time of 36 months of ART follow up by adjusting adherence, age and gender (Table 4).

Discussion

In Ethiopia HAART scale up began in 2005 and since then its coverage was 82.8% by 2015 [14]. HAART guideline in Ethiopia is given a combination of two Nucleoside transcriptase inhibitors (NRTI) and one Non-nucleoside transcriptase inhibitor (NNRTI). The first line regimens are Lamivudine (3TC) combined with Stavudine (d4T), zidovudine (AZT) or Tenofovir (TDF), and either nevirapine (NVP) or efavirenz (EFV) (Table 2). However, d4T is discontinued due to its known long term mitochondrial toxicity and substituted either by AZT or TDF. For anemic patients TDF substitutes AZT and for tuberculosis patients treated with Rifampicin EFV replaces NVP.

This study described immunological and virological failure and associated risk factors among HIV infected individuals on first-line regimen from 6 months to 9 years duration on ART. Twenty nine (11.2%) of the study participants were under the category of clinical WHO stage IV at ART initiation. After 6 months of ART, WHO stage IV cases had decreased to 13 (5.0%) and fall to 1 (0. 4%) after median time of 36 months ART follow up. This was similar to a study conducted in Surat, India [17].

Majority (93.1%) of the study participants had good adherence (≥ 95%) to treatment, similar value to one study conducted in Colombia 92% [18]. However, our result was higher than the reports from Addis Ababa 78.5% [19], Gonder (82.7% [20] and 85.8% [21], southern Ethiopia 81.8% [22], and New Guinea 82.4% [23]. On the other hand, our finding was lower when compared to Addis Ababa 97.7% [24] and Jimma 100% [25]. These variations in patient adherences may be possibly related with psychosocial support, stigma, lack of commitment to take medications, not feeling well, fear of side effects and being busy or forgetting [12, 26, 27].

The median baseline CD4+ counts of the study participants was 162 cells/μL. This was comparable with the studies conducted in southern Ethiopia 156 cell/μL [22] and Kenya 152 cells/μL [28], but higher than that of Addis Ababa 115 cells/μL [19]. Studies from Addis Ababa 177 cells/μL [24], Jimma 191 cells/μL [25], and Liberia 238 cell/μL [29] have reported higher median CD4+ count than our study. This variation may be explained with differences in time of initiation of ART in patients infected by HIV for long period of time. Since long duration of HIV infection without initiation of ART favors viral replication which in turn leads to lower CD4+ count.

Table 3. (Continued)

| Characteristics | Immunological failure | Binary logistic regression | Multiple logistic regression |
|-----------------|-----------------------|---------------------------|----------------------------|
|                 | Yes N (%) | N* N (%) | p- value | OR(95%CI) | p- value | AOR(95%CI) |
| Yes             | 3(27.3)  | 8 (72.7) | NA       |          |          |           |
| No              | 8(6.3)   | 120(93.8)|          |          |          |           |

HCV co-infection(n = 64)

|             | Yes | N (%) | N* N (%) | p- value | OR(95%CI) | p- value | AOR(95%CI) |
|-------------|-----|-------|----------|----------|-----------|----------|------------|
| Yes         | 1(50) | 1(50)   | NA       |          |          |          |            |
| No          | 3(4.8) | 59(95.2)|          |          |          |          |            |

https://doi.org/10.1371/journal.pone.0196259.t003
Table 4. Virological failure and associated risk factors among HIV infected individuals on ART from January 2008 to March 2016 at Mekelle hospital and Ayder Comprehensive Specialized Hospital (n = 30).

| Characteristics                          | Virological Failure | Binary logistic regression | Multiple logistic regression |
|------------------------------------------|---------------------|---------------------------|-----------------------------|
|                                          | Yes N° (%)          | No N° (%)                 | p-value | OR (95% CI) | p-value | AOR (95% CI) |
| Gender                                   |                     |                          |         |             |         |             |
| Male                                     | 20(18.3)            | 89(81.7)                 | 0.005   | 3.17(1.4–7.08) | 0.002   | 4.6(1.72–12.33) |
| Female                                   | 10(6.6)             | 141(93.4)                |         |             |         |             |
| Age group(years)                         |                     |                          |         |             |         |             |
| <40                                      | 22(15.6)            | 119(84.4)                | 0.03    | 2.57(1.10–6.00) | 0.005   | 4.43(1.57–12.46) |
| ≥40                                      | 8(6.7)              | 111(93.3)                |         |             |         |             |
| Age group at initiation of ART(years)    |                     |                          |         |             |         |             |
| <35                                      | 18(14.9)            | 103(85.1)                | 0.12    | 1.85(0.85–4.02) | 0.005   | 4.43(1.57–12.46) |
| ≥35                                      | 12(8.6)             | 127(91.4)                |         |             |         |             |
| CD4+ count (cells/μL) at base line       |                     |                          |         |             |         |             |
| ≤250                                     | 21(13.3)            | 137(86.7)                | 0.27    | 1.58(0.70–3.61) | 0.040   | 2.81(1.051–7.51) |
| >250                                     | 9(8.8)              | 93(91.2)                 |         |             |         |             |
| CD4+ count (cells/μL) after median time of 36 months of ART follow up | | | | | | |
| ≤250                                     | 15(30)              | 35(70)                   | 0.000   | 5.57(2.50–12.4) | 0.040   | 2.81(1.051–7.51) |
| >250                                     | 15(7.2)             | 195(92.9)                |         |             |         |             |
| Time on ART(months)                      |                     |                          |         |             |         |             |
| <36                                      | 16(15.2)            | 89(84.8)                 | 0.13    | 1.81(0.84–3.90) | 0.00   | 16.37(4.65–57.68) |
| ≥36                                      | 14(9)               | 141(91)                  |         |             |         |             |
| Regimen given at base line               |                     |                          |         |             |         |             |
| TDF 3TC EFV                              | 10(6.1)             | 155(93.9)                | NA      |             |         |             |
| AZT 3TC NVP                              | 9(25)               | 27(75)                   |         |             |         |             |
| AZT 3TC EFV                              | 6(31.6)             | 13(68.4)                 |         |             |         |             |
| TDF 3TC NVP'                             | 3(20)               | 12(80)                   |         |             |         |             |
| Other                                    | 2(8)                | 23(92)                   |         |             |         |             |
| Adherence                                |                     |                          |         |             |         |             |
| Fair/poor                                | 11(61.1)            | 7(38.9)                  | 0.00    | 18.44(6.41–12.08) | 0.00   | 16.37(4.65–57.68) |
| Good                                     | 19(7.9)             | 223(92.1)                |         |             |         |             |
| WHO clinical stage at base line          |                     |                          |         |             |         |             |
| I/II                                     | 14(11.3)            | 110(88.7)                | 0.91    | 1.03(0.45–2.05) | 0.91   | 1.03(0.45–2.05) |
| III/IV                                   | 16(11.8)            | 120(88.2)                |         |             |         |             |
| History of malnutrition                  |                     |                          |         |             |         |             |
| Yes                                      | 14(16.9)            | 69(83.1)                 | 0.07    | 2.04(0.95–4.41) | 0.07   | 2.04(0.95–4.41) |
| No                                       | 16(9)               | 161(91)                  |         |             |         |             |
| History of opportunistic infections      |                     |                          |         |             |         |             |
| Yes                                      | 19(13.3)            | 124(86.7)                | 0.33    | 1.48(0.67–3.24) | 0.07   | 4.40(0.89–21.81) |
| No                                       | 11(9.4)             | 106(90.6)                |         |             |         |             |
| Chronic non communicable disease         |                     |                          |         |             |         |             |
| Yes                                      | 5(38.5)             | 8(61.5)                  | 0.015   | 5.55(1.69–18.27) | 0.07   | 4.40(0.89–21.81) |
| No                                       | 25(10.1)            | 222(89.9)                |         |             |         |             |
| TB co-infection                          |                     |                          |         |             |         |             |
| Yes                                      | 4(9.3)              | 39(90.7)                 | NA      |             |         |             |
| No                                       | 26(12)              | 191(88)                  |         |             |         |             |
| HIV prophylaxis given                    |                     |                          |         |             |         |             |
| Yes                                      | 0(0)                | 12(100)                  | NA      |             |         |             |
| No                                       | 30(12.1)            | 218(87.9)                |         |             |         |             |

(Continued)
Immunological failure was found to be 6.5% in a median time of 36 month of ART follow up. Our finding was similar with a study conducted in Liberia 5.1% [29]. However, it was much lower than the findings in other parts of Ethiopia: southern Ethiopia 11.5% [22], Jimma 9.8% [25], Addis Ababa 15.7% [19] and 15% [24], Gonder 15.1% [20], and other studies outside Ethiopia: Kenya 64.4% [28], Tanzania 25% [30], China 18.4% [31], Colombia 14% [18], Thailand 33.5% [32], and Nepal 35% [33].

This variation in immunological failure may be related with the WHO guideline which varies overtime. For example, in our study immunological failure was defined based on the 2016 WHO guideline, as fall of CD4+ count below 250 cells/μL following clinical failure, or persistent CD4+ count below 100 cells/μL [12]. However, the aforementioned researchers [19,20,22,25,28,30,31] defined immunological failure based on previous WHO guidelines as fall of CD4+ count to baseline or below sever immune suppression (CD4+ count < 200 cells/μL) [31], 50% fall from on-treatment peak [19,24,22,31] or fall by 30% from on treatment peak value [28,30], failure to achieve CD4+ count > 350 cells/μL despite virological suppression [32], CD4+ count < 350 cells/μL [33]; in addition to persistent CD4+ count below 100 cells/μL.

Besides, higher immunological failure in other studies may be attributed to the higher non-adherence rate [19, 20, 22], compared with our study.

Non-adherent individuals were 5.68 times more likely to experience immunological failures than those who had good adherence (p = 0.021). This is in tandem with the study conducted in Gonder [20], southern Ethiopia [28], Colombia [18] and France [34]. Possibly this explanation may be due to the fact that poor adherence allow more viral replication which in turn increases infection of more CD4+ cells and ultimately depletion of their number.

Immunological failure was 3.8 times more likely to occur in TB co-infected individuals compared to TB non infected individuals (p = 0.003). This was similar with reports from southern Ethiopia [28], Gonder [20, 35] and Nigeria [36]. This indicated that TB infection impairs cellular immune responses through M.tuberculosis-induced apoptosis of CD4 cells which subsequently lead to depletion of CD4+ cells and results in immunological failure [37].

Study participants with HIV RNA level ≥1000 copies/mL showed 12.33 times more likely to experience immunological failure (p <0.001) in a median time of 36 months of ART follow up as compared with those who have HIV RNA level less than 1000 copies/mL. Similar results have been reported from India [38], Nepal [33], Thailand [39], London [40], and USA [41].

The overall virological failure (viral load ≥1000 copies/mL) in this study was seen in 30 (11.5%) study participants. This was similar with a study conducted in Gonder 11.8% [21], Addis Ababa 15% [21], New Guinea 13.7% [23], Uganda 14.5% [42], China 13.4% [31], Thailand 9.6% [32], Nepal 9.9% [33] and Cambodia 12.9% [43]. However, our result was higher than findings from studies conducted in Jimma 5.3% [25] and Burkina Faso 7.5% [44]. This variation may be due to difference in interventions for optimization of patient’s adherence and type of regimen given. For example, protease inhibitors were used as first line regimen in Burkina Faso [44] and nutritional support was given for the study participants [25] which were different from our setting.

| Table 4. (Continued) |
|----------------------|------------------|-----------------|-----------------|
| Characteristics      | Virological Failure | Binary logistic regression | Multiple logistic regression |
|                      | Yes N˚ (%) | No N˚ (%) | p-value | OR(95%CI) | p-value | AOR(95%CI) |
| Income(birr)         |          |          |        |          |        |
| ≤1500                | 13(9.6)  | 123(90.4) | 0.3    | 0.67(0.31–1.43) |        |          |
| >1500                | 17(13.7) | 107(86.3) |        |          |        |          |

https://doi.org/10.1371/journal.pone.0196259.t004
Unlike our result, higher virological failure was reported from Kenya 23.7% [45] and 24.6% [46], Liberia 47% [29], Zimbabwe 30.6% [47], Tanzania 57.1% [30], 32% [48], Cameroon 20.6% [49], Ghana 16.7% [50], Togo 51.6% [51], Colombia 20.9% [18], India 69.6% [38] and Peru 24% [52]. This difference may be due to lower treatment adherence compared with our study [48, 52]. The other possible reason may due to differences in definition of virological failure, where plasma viral load $\geq$ 400 copies/mL was used as cut-off point for virological failure [30, 45, 46] and inclusion criteria used. For example, the study participants included in those studies were clinically/immunologically failed [29, 39] and perinatally infected [51], and had lower median age (9.5 years old) [49] and shorter median time on ART (7.8 months) [50].

Non-adherence was strongly associated with virological failure (AOR = 16.37, $p < 0.001$), this was comparable with a studies conducted in Gonder [21], Uganda [53], New Guinea [23], Colombia [18], Kenya [46], Tanzania [48,54], Peru [52] and Thailand [32]. This is because low level of antiretroviral in the body owing to the non-adherence is not sufficient to suppress viral replication, hence leads to detection of HIV RNA level in the blood [53].

Likewise, being male was 4.6 fold risk to develop virological failure ($p = 0.002$) than females and this was lined with a study conducted in Burkina Faso [44], Swaziland [55] and Nigeria [56]. Similarly higher virological failure, but statistically non-significant was reported from Zimbabwe [47, 57], Kenya [28], Nepal [33], result of worldwide systemic review [58] and Colombia [18]. Possible explanation for virological failure among males has been speculated due to their low health–seeking behavior [26, 44, 56] as compared to females.

Virological failure was 4.43 times more likely to happen in individuals aged less than 40 years old (AOR(95% CI) = 4.43(1.57–12.46), $p = 0.005$). This was supported by several studies conducted in Kenya [28, 47], South Africa [59], Burkina Faso [44], Swaziland [55], result of systemic review in Sub Saharan Africa [26], India [38], Thailand [32] and Johns Hopkins- North Carolina University [60]. The possible explanation for this may be due to difference in maturity or lifestyle stability or may be due to work load and hence may forget to take medication properly. However, this needs further study.

Low CD4$^+$ count may reflect viral replication due to treatment interruption or resistance [61]. This appears consistent relationship between current CD4$^+$ count and odds of virological failure. Those who had CD4$^+$ count $< 250 \text{ cells/μL}$ were 2.81 times more likely to have virological failure ($p = 0.040$) in a median time of 36 months of ART as compared with those whose CD4$^+$ count was $\geq 250 \text{ cells/μL}$. This association was similar with studies conducted in Tanzania [48], Swaziland [55] and Peru [52]. Though not statistically significant, studies conducted from Burkina Faso [44] and Boston [62] have supported our result.

**Limitation of the study**

Our study was not without limitation. One may argue that taking consecutive viral load measurements would be a better strategy to determine the virological failure than a single measurement. However, in Ethiopia and mainly in the study area, patients on HAART were followed using CD4+ count and WHO clinical stages. Hence we were unable to get data on viral load from the patient’s chart and that could be our limitation of the study. Due to the budget limitations, we only did a single viral load measurement during the collection time. Therefore, researches using consecutive viral load measurements are needed to have a representative data on the virological failures in the country.

**Conclusion**

After a median time of 36 months on ART, virological and immunological failure in the study area were (11.5%) and 17(6.5%), respectively. Non-adherence, aged $< 40$ years old, having
CD4$^+$ count $< 250$ cells/$\mu$L in a median time of 36 months on ART, and male gender were predictors for virological failure. Similarly, non-adherence, TB co-infection and HIV RNA level $\geq 1000$ copies/mL were associated with immunological failure. Hence our result highlights the need for more commitment and effort from all stakeholders on these predictors so as to sustain the long term efficacy of HAART thereby achieving the ambitious target of 2020.

Supporting information

S1 Table. Questionnaire.
(DOCX)

S2 Table. Raw patients’ data.
(SAV)

Acknowledgments

Our appreciation goes to Mekelle University, College of Health Sciences and study participants for financial support and voluntarily participation, respectively. Our gratitude also goes to Mrs. Alefech Addisu and Mr. Nesredin Ftwi for their incredible support in viral load determination.

Lastly we are indebted to the Tigray public health laboratory research for providing reagents to do viral load measurements.

Author Contributions

Conceptualization: Genet Gebrehiwet Hailu, Dawit Gebregziabher Hagos, Araya Gebreyesus Wasihun, Tsehaye Asmelash Dejene.

Data curation: Genet Gebrehiwet Hailu, Amlsha Kahsay Hagos.

Formal analysis: Araya Gebreyesus Wasihun.

Funding acquisition: Amlsha Kahsay Hagos.

Methodology: Genet Gebrehiwet Hailu, Dawit Gebregziabher Hagos, Amlsha Kahsay Hagos, Araya Gebreyesus Wasihun, Tsehaye Asmelash Dejene.

Project administration: Genet Gebrehiwet Hailu.

Supervision: Dawit Gebregziabher Hagos, Amlsha Kahsay Hagos, Araya Gebreyesus Wasihun, Tsehaye Asmelash Dejene.

Writing – original draft: Genet Gebrehiwet Hailu, Araya Gebreyesus Wasihun.

Writing – review & editing: Genet Gebrehiwet Hailu, Amlsha Kahsay Hagos, Araya Gebreyesus Wasihun, Tsehaye Asmelash Dejene.

References

1. Pallela F, Loveless MO, Fuhrer J, Satten GA and Aschman DJ. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. NEJM, 1998; 338 (13):853–860.

2. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report. Geneva, Switzerland; 2009.

3. Wegbreit J, Bertozzi S, DeMaria LM and Padian NS. Effectiveness of HIV prevention strategies in resource-poor countries: tailoring the intervention to the context. AIDS, 2006; 20:1217–35. https://doi.org/10.1097/01.aids.0000232229.96134.56 PMID: 16816550
4. Moore DM, Hogg RS, Yip B, Wood E, Tyndall M, Braithwaite P, et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. *J Acquir Immune Defic Syndr*, 2005; 40(3):288–293. PMID: 16249702

5. Hogg R, Lima V, Sterne JA, Grabar S, Battegay M, Bonarek M et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. *Lancet*, 2008; 372(9635):293–299. https://doi.org/10.1016/S0140-6736(08)61113-7 PMID: 18657708

6. Ekstrand ML, Collier AC, Kalish LA, Assmann SF, Fianigan TP et al.; Viral Activation Transfusion Study Investigators. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. *Ann Intern Med*, 2001; 135:17–26. PMID: 11434728

7. Clavel F, Hance AJ. HIV drug resistance. *NEJM*, 2004; 350:1023–35. https://doi.org/10.1056/NEJMra025195 PMID: 14999114

8. Murphy EL, Collier AC, Kalish LA, Assmann SF, Fianigan TP et al.; Viral Activation Transfusion Study Investigators. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. *Ann Intern Med*, 2001; 135:17–26. PMID: 11434728

9. D’Amato RM, D’Aquilia RT, Wein LM. Management of antiretroviral therapy for HIV infection: modeling when to change therapy. *Antivir Thér*, 1998; 3:147–58. PMID: 10862132

10. WHO. Towards universal access: Scaling up priority HIV/AIDS intervention in health sector. Geneva, 2008.

11. Koenig SP, Leandre F, and Farmer PE. Scaling-up HIV treatment programs in resource-limited settings: The rural Haiti experience. *AIDS*, 2004; 18 (I):S21–S25.

12. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach—2nd ed. Geneva, Switzerland, WHO, 2016.

13. The Joint United Nations Programme on HIV/AIDS (UNAIDS). Global HIV statistics. Fact sheet July, 2017.

14. Federal Democratic Republic of Ethiopia Ministry of health. HSDP IV: annual performance report.2014/2015.Version 1, 2015.

15. Tsegaye E, Worku A. Assessment of antiretroviral treatment outcome in public hospitals, South Nations Nationalities and Peoples Region, Ethiopia. *Ethiop J Health Dev*, 2011; 25(2):102–109.

16. The Government of Regional States of Tigray. Report on the health status of Tigray Region, Mekelle; 2014.

17. Patel A, Trivedi S S, Chudasama RK and Patel PK. Effect of antiretroviral therapy on clinical and immunologic disease progression in HIV positive children: One-year follow-up study. *J Family Community Med*, 2012; 19(3):179–183. https://doi.org/10.4103/2330-8229.102316 PMID: 23230384

18. De La Hoz JM, Bolíano L, Cárdenas O, González R, Sabbag J, Palacio L et al. Charactrization of treatment failure in HIV positive patients in the Columbian Caribbean region. *Colomb med(Cali)*, 2014; 45(4):162–167.

19. Teshome W and Tefera A. Detection of immunological treatment failure among HIV infected patients in Ethiopia: a retrospective cohort study. *BMC Immunology*, 2015; 16:55. https://doi.org/10.1186/s12865-015-0120-1 PMID: 26376828

20. Zeleke A. Prevalence of antiretroviral treatment failure and associated factors in HIV infected children on antiretroviral therapy at Gondar University Hospital, retrospective cohort study. *Int. J Med Med Sci*, 2016; 8(11):125–132.

21. Mulu A, Maier M and Liebert UG. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study. *PLoS ONE*, 2015; 10(10): e0141318. https://doi.org/10.1371/journal.pone.0141318 PMID: 26512902

22. Yirdaw KD, Hattingh S. Prevalence and Predictors of Immunological Failure among HIV Patients on HAART in Southern Ethiopia. *PLoS ONE*, 2015; 10(5):e0125826. https://doi.org/10.1371/journal.pone.0125826 PMID: 25961732

23. Gare J, Kelly-Hanku A, Ryan CE, David M, Kaima P, Imara U, et al. Factors Influencing Antiretroviral Adherence and Virological Outcomes in People Living with HIV in the Highlands of Papua New Guinea. *PLoS ONE*, 2015; 10(8): e0134918. https://doi.org/10.1371/journal.pone.0134918 PMID: 26244516

24. Teshome YY, Yalew AW. Magnitude and Predictors of Anti-Retroviral Treatment (ART) Failure in Private Health Facilities in Addis Ababa, Ethiopia. *PLoS ONE*, 2015; 10(8): e0126026. https://doi.org/10.1371/journal.pone.0126026 PMID: 25946065

25. Abdisa A, Yilma D, Fonager J, Audelin M A, Christensen HL, Mette FO et al. Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia. *BMC Infectious Diseases*, 2014; 14:181. https://doi.org/10.1186/1471-2334-14-181 PMID: 24708645
26. Heestermans T, Browne JL, Atienz SC, Vervoort SC, Kiplstein-Grobusch K. Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub-Saharan Africa: a systematic review. *BMJ Global Health*, 2016; 1:e000125. https://doi.org/10.1136/bmjgh-2016-000125 PMID: 28588979

27. Wakabi SN, Ng’ang’a ZW and Mbugua GG. Factors associated with non-adherence to highly active antiretroviral therapy in Nairobi, Kenya. *AIDS Research and Therapy*, 2011; 8:43. https://doi.org/10.1186/1742-6405-8-43 PMID: 2214125

28. Sang RKA, Miruka FO. Factors Associated with Virologic Failure Amongst Adults on Antiretroviral Therapy in Nyania Region, Kenya. *JOSR-JDMS*, 2016; 15(7):108–121.

29. Loubet P, Charpentier C, Visseaux B, Borbor A, Nuta C, Adu E et al. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study. *J Antimicrob Chemother*, 2015; 70(6):1881–4. https://doi.org/10.1093/jac/dkv030 PMID: 25698771

30. Mgelela EM, Kitsenge R, Aboud S. Detecting virological failure in HIV-infected Tanzanian children. *S Afr Med J*, 2014; 104(10):696–699. https://doi.org/10.7196/samj.7807 PMID: 25363057

31. Huang P, Tan J, Ma W, Zheng H, Lu Y, Wang N et al. Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003–2014. *BMJ Open*, 2015; 5:e007508. https://doi.org/10.1136/bmjopen-2014-007508 PMID: 26026691

32. Khienprasit N, Chaiwarith R, Sirisanthana T and Supparatpinyo K. Incidence and risk factors of antiretroviral treatment failure in treatment-naive HIV-infected patients at Chiang Mai University Hospital, Thailand. *AIDS Research and Therapy*, 2011; 8:42. https://doi.org/10.1186/1742-6405-8-42 PMID: 22060823

33. Ojha C R, Shyakya G and Dumre S P. Virological and Immunological Status of the People Living with HIV/AIDS Undergoing ART Treatment in Nepal. *BioMed Research International*, 2016; 2016: 6817325. https://doi.org/10.1155/2016/6817325 PMID: 27547761

34. Raffi F, Le Moing V, Assi N, Habak S, Spire B, Cazanave C et al. Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course. *J Antimicrob Chemother*, 2017; 72(1):240–245. https://doi.org/10.1093/jac/dkw369 PMID: 27629069

35. Assela A, Gelay B, Getnet G and Yitayew G. The effect of incident tuberculosis on immunological response of HIV patients on highly active anti-retroviral therapy at the university of Gondar hospital, northwest Ethiopia: a retrospective follow-up study. *BMC Infectious Diseases*, 2014; 14:468. https://doi.org/10.1186/1471-2334-14-468 PMID: 25164855

36. Musa BM, Musa B, Muhammed H, Ibrahim N, Musa AG. Incidence of tuberculosis and immunological profile of TB/HIV co-infected patients in Nigeria. *Annals of Thoracic Medicine*, 2015; 10(3):185–192. https://doi.org/10.4103/1817-1737.160838 PMID: 26229561

37. Zhang Q, Sugawara I. Immunology of tuberculosis. *World J Exp Med*, 2012; 2(4):70–74. https://doi.org/10.5493/wjem.v2.i4.70 PMID: 24520536

38. Raja K, Chandrasekar C, Krishnarajasekhar OR, Ravichandran N, Kumar S, Manoharan G, Sharmila IA. Predicting Virological Failure with Immunological Criteria in First Line ART Patients in a Resource Poor Setting. *World Journal of AIDS*, 2014; 4: 413–421.

39. Puthanakit T, Kerr SJ, Ananwaranich J, Bunupuradah T, Boonrak P and Sirisanthana V. Pattern and Predictors of Immunological Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral Therapy. *Pediatr Infect Dis J*, 2009; 28(6):488–492. PMID: 19504731

40. Smith CJ, Sabin CA, Youle MS, Kinloch-de Loeis S, Lampe FC, Madge Set al. Factors Influencing Increases in CD4 Cell Counts of HIV-Positive Persons Receiving Long-Term Highly Active Antiretroviral Therapy. *JID*, 2004; 190(15):1860–8.

41. Loka J, Boscha RJ, Benson BA, Collier AC, Robbins KG, Shafere RW et al. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. *AIDS*, 2010; 24(12): 1867–1876. https://doi.org/10.1097/QAD.0b013e32833adbcf PMID: 20467286

42. von Braun A, Sekagya-Wiltshire C, Scherrer AU, Magambo B, Kambugu A, Fehr J and Castelnuovo B. Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis. *AIDS Res Ther*, 2017; 14:1–6. https://doi.org/10.1186/s12977-016-0182-5 PMID: 28086929

43. Barennes H, Guillet S, Limsreng S, Him S, Nounin J, Hak C et al. Virological Failure and HIV-1 Drug Resistance Mutations among Naive and Antiretroviral Pre-Treated Patients Entering the ESTHER Program of Calmette Hospital in Cambodia. *PLoS ONE*, 2014; 9(8):e105736. https://doi.org/10.1371/journal.pone.0105736 PMID: 25166019

44. Penot P, He‘ma a Bado G, Kabore F, Sore I, Zombie D et al. The vulnerability of men to virologic failure during antiretroviral therapy in a public routine clinic in Burkina Faso. *JIAS*, 2014; 17:18646.
45. Hassan AS, Nabwera HM, Mwaringa SM, Obonyo CA, Sanders EJ, Rinke de Wit TF et al. HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study. *AIDS Research and Therapy*, 2014; 11:9. https://doi.org/10.1186/1747-2460-11-9 PMID: 24456757

46. Makadzange AT, Higgins-Biddle M, Chimukangara B, Birri R, Gordon M, Mahlanza T, et al. Clinical, Virologic, Immunologic Outcomes and Emerging HIV Drug Resistance Patterns in Children and Adolescents in Public ART Care in Zimbabwe. *PLoS ONE*, 2015; 10(12): e0144057. https://doi.org/10.1371/journal.pone.0144057 PMID: 26658814

47. Ramadhani HO, Thielman NM, Landman KZ, Ndosi EM, Gao F, Kirchherr JL et al. Predictors of Incomplete Adherence, Virologic Failure, and Antiviral Drug Resistance among HIV-Infected Adults Receiving Antiretroviral Therapy in Tanzania. *CID*, 2007; 45:1492–8.

48. Nlend AEN, Lyeb S, Moyo STN and Motaze AN. Viral Monitoring and Prevalence of Viral Failure in HIV-1 Infected Children under First Line Antiretroviral Therapy during the First 60 Months of Treatment in Yaoundé, Cameroon: A Serial Cross Sectional Analysis. *Open Journal of Pediatrics*, 2016; 6:69–74.

49. Barry O, Powell J, Renner L, Bonney EY, Prin M, Ampofo W et al. Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in Ghana. *BMC Infectious Diseases*, 2013; 13:476. https://doi.org/10.1186/1471-2334-13-476 PMID: 24119088

50. Salou M, Dagnra AY, Butel C, Vidal N, Serrano L, Takassi E et al. High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo. *JIAS*, 2016; 19:20683.

51. Jorge AR, Jorge PB, Elsa GL, Miguel CS, Rodriguez M, Willig J and Juan EZ. Risk factors associated with virologic failure in HIV-infected patients receiving antiretroviral therapy at a public hospital in Peru. *Rev Chilena Infectol*, 2013; 30(1): 42–48. https://doi.org/10.4067/S0716-1018201300000100006 PMID: 23450408

52. Ahousa L, Guenther G, Pinoges L, Anguzu P, Chaix M, Le Tiec C et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. *BMC Infectious Diseases*, 2009; 9:81. https://doi.org/10.1186/1742-6405-9-81 PMID: 19493344

53. Dow DE, Shayo AM, Cunningham CK and Reddy EA. Durability of antiretroviral therapy and predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up. *BMC Infectious Diseases*, 2014; 14:567. https://doi.org/10.1186/s12879-014-0567-3 PMID: 25373425

54. Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B et al. Factors Associated with Virological Failure and Suppression after Enhanced Adherence Counselling, in Children, Adolescents and Adults on Antiretroviral Therapy for HIV in Swaziland. *PLoS ONE*, 2015; 10(2): e0116144. https://doi.org/10.1371/journal.pone.0116144 PMID: 25695494

55. Dalhatu I, Onotu D, Odafe S, Abiri O, Debem H, Agolory S et al. Outcomes of Nigeria’s HIV/AIDS Treatment Program for Patients Initiated on Antiretroviral Therapy between 2004–2012. *PLoS ONE*, 2016; 11(11): e0165528. https://doi.org/10.1371/journal.pone.0165528 PMID: 27829033

56. Chawana TD, Reid A, Bwakura T, Gavi S, Nhachi CFB. Factors influencing treatment failure in HIV-positive adult patients on first line antiretroviral therapy. *Cent Afr J Med*, 2014; 60(5-8):29–36.

57. Castilho JL, Melekhin VV and Sterling TR. Sex Differences in HIV Outcomes in the Highly Active Antiretroviral Therapy Era: A Systematic Review. *AIDS research and human retroviruses*, 2014; 30(5):446–456. https://doi.org/10.1089/AID.2013.0208 PMID: 24401107

58. Hare AQ, Ordonez CE, Johnson BA., Rio DC, Kearns RA., Wu B et al. Gender-specific risk factors for virologic failure in KwaZulu-Natal: Automobile ownership and financial insecurity. *AIDS Behav*, 2014; 18(11): 2219–2229. https://doi.org/10.1007/s10461-014-0849-1 PMID: 25037488

59. Patterson K, Napravnik S, Eron J, Keruly J and Moore R. Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy. *HIV Medicine*, 2007; 8:406–410. https://doi.org/10.1111/j.1468-1293.2007.00485.x PMID: 17661850

60. Seyler C, Adje-Touré C, Messou E, Dakoury-Dogbo N, Rouet F, Gabillard D et al. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. *AIDS*, 2007; 21(9): 1157–1164. https://doi.org/10.1097/QAD.0b013e3281c615da PMID: 17502726

61. Robbins GK, Johnson KL, Chang Y, Jackson KE, Sax PE, Meigs JB and Freedberg KA. Predicting Virologic Failure in an HIV Clinic. *CID*, 2010; 50:779–786.